Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma

Shawn O. Streeter, PharmD, Omar Nadeem, MD, Paul G. Richardson, MD, Jacob P. Laubach, MD, Clifton C. Mo, MD, Kimberly Noonan, RN, NP, AOCN, Mary McKenney, NP, Tina Flaherty, ANP-BC, AOCN, Virginia Dalton, MS, APRN, Anil Aktas-Samur, PhD, Houry Leblebjian, PharmD, BCOP

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-143385

Published: 2020

Journal Articles

Treating MRD Positivity in Multiple Myeloma: An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Long-Term Remissions in Patients with Low Disease Burden

Luca Biavati, MD, Carol Ann Huff, MD, Anna Ferguson, BSN, RN, Lakshmi Rudraraju, MS, Cristina Zucchinetti, Rachel Gittelman, Sarah Johnson, Catherine Sanders, Abbas Abbas Ali, MD, Kimberly Noonan, PhD MPH, Ivan M. Borrello, MD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-142620

Published: 2020

Journal Articles

An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Durable Remissions and Sustained Immunological Responses in Multiple Myeloma

Luca Biavati, MD, Anna Ferguson, BSN, RN, Carol Ann Huff, MD, Lakshmi Rudraraju, MS, Rachel Gittelman, Sarah Johnson, Catherine Sanders, Syed Abbas Ali, MD, Kimberly Noonan, PhD MPH, Ivan M. Borrello, MD

Blood (2019) 134 (Supplement_1): 1895.

https://doi.org/10.1182/blood-2019-128430

Published: 2019

Journal Articles

Superior Efficacy of CAR-T Cells Using Marrow-Infiltrating Lymphocytes (MILs TM ) As Compared to Peripheral Blood Lymphocytes (PBLs)

Eric R. Lutz, PhD, Srikanta Jana, PhD, Lakshmi Rudraraju, MS, Elizabeth DeOliveira, Jing Zhou, Sean Mackay, Ivan M. Borrello, MD, Kimberly Noonan, PhD MPH

Blood (2019) 134 (Supplement_1): 4437.

https://doi.org/10.1182/blood-2019-130629

Published: 2019

Journal Articles

Marrow-Infiltrating Lymphocytes (MILs) Provide a Robust Platform for CAR-T Cell Therapy

Eric R. Lutz, PhD, Valentina Hoyos, MD, Lakshmi Rudraraju, MS, Elizabeth DeOliveira, Srikanta Jana, PhD, Ido Weiss, PhD, Ivan M. Borrello, MD, Kimberly Noonan, PhD MPH

Blood (2018) 132 (Supplement 1): 3337.

https://doi.org/10.1182/blood-2018-99-118580

Published: 2018

Journal Articles

Progression Risk-Based Classification of Asymptomatic Waldenström Macroglobulinemia

Blood (2018) 132 (Supplement 1): 150.

https://doi.org/10.1182/blood-2018-99-114324

Published: 2018

Journal Articles

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Chia-jen Liu, MD, Irene M. Ghobrial, MD, Mark Bustoros, MD, Kaitlen Reyes, NP, Kalvis Hornburg, BA, Ashraf Z. Badros, MD, James J. Vredenburgh, MD, Adam Boruchov, MD, Jeffrey V Matous, MD, Aaron Caola, BS, Bradley Rivotto, BS, Alexandra Savell, BS, Patrick Henrick, BS, Claudia E. Paba-Prada, MD, Robert L. Schlossman, MD, Jacob Laubach, MD, Jacalyn Rosenblatt, MD, Andrew J Yee, MD, Omar Nadeem, MD, Rodrigo O. Maegawa, MD, Andrzej Jakubowiak, MD PhD, Saad Z. Usmani, MD, Manisha Bhutani, MD, Joseph Cappuccio, BS, Brianna Berrios, BS, Kimberly Noonan, NP, Oksana Zavidij, PhD, Tarek H Mouhieddine, MD, Cody J Boehner, Carl-Jannes Neuse, Karma Ziad Salem, MD, Mairead Reidy, PhD, Jihye Park, PhD, Michael Agius, PhD, Mahshid Rahmat, PhD, Salomon Manier, MD PhD, Divaya Bhutani, MD, Jeffrey A Zonder, MD, Nikhil Munshi, MD, Daniel Auclair, PhD, Kenneth Anderson, MD, Paul Richardson

Blood (2018) 132 (Supplement 1): 154.

https://doi.org/10.1182/blood-2018-154

Published: 2018

Journal Articles

Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression

Blood (2017) 130 (Supplement 1): 392.

https://doi.org/10.1182/blood.V130.Suppl_1.392.392

Published: 2017

Journal Articles

Impact of Bone Marrow Biopsy on Risk Stratification of Low-Risk IgG MGUS Patients

Blood (2017) 130 (Supplement 1): 5397.

https://doi.org/10.1182/blood.V130.Suppl_1.5397.5397

Published: 2017

Journal Articles

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2016) 128 (22): 976.

https://doi.org/10.1182/blood.V128.22.976.976

Published: 2016

Journal Articles

Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Blood (2015) 126 (23): 4256.

https://doi.org/10.1182/blood.V126.23.4256.4256

Published: 2015

Journal Articles

Allogeneic Myeloma GVAX with Lenalidomide Enhances Progression Free Survival through the Generation of Tumor Specific Immunity in Patients in Near Complete Remission

Ivan M. Borrello, MD, Kimberly Noonan, PhD MPH, Carol Ann Huff, Anna Ferguson, BSN, RN, Amy Sidorski, CRNP, Lakshmi Rudraraju, Raffaello Cimbro, MS, Luigi Marchionni, MD PhD

Blood (2015) 126 (23): 4238.

https://doi.org/10.1182/blood.V126.23.4238.4238

Published: 2015

Journal Articles

Impaired Response to Influenza Vaccination in AML Patients Post-Chemotherapy Associated with a Highly Atypical B-Cell Profile

Meghali Goswami, Gabrielle T. Prince, MD, Angelique Biancotto, PhD, Susan Moir, PhD, Foo Cheung, PhD, Yuri Kotliarov, PhD, Kimberly Dunham, Jinguo Chen, MD, Rongye Shi, MD, Huizhi Zhou, Hana Golding, PhD, Jingrong Tang, MD PhD, John S. Tsang, PhD, Howard B. Dickler, MD, Kimberly Noonan, PhD MPH, B. Douglas Smith, MD, Ivan M. Borrello, MD, Christopher S. Hourigan, MD PhD

Blood (2015) 126 (23): 3427.

https://doi.org/10.1182/blood.V126.23.3427.3427

Published: 2015

Journal Articles

Lenalidomide Immunomodulation with an Allogeneic Myeloma GVAX in a Near Complete Remission Induces Durable Clinical Remissions

Kimberly Noonan, PhD MPH, Carol Ann Huff, Amy Sidorski, NP, Anna Ferguson, RN, Lakshmi Rudraraju, MS, Andrea Casildo, BS, Ivan Borrello, MD

Blood (2014) 124 (21): 2137.

https://doi.org/10.1182/blood.V124.21.2137.2137

Published: 2014

Journal Articles

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, MD, Robert Allyn Redd, MS, Jeffrey Matous, Philippe Armand, MD PhD, Erica N Boswell, BS, Stacey Chuma, BSN, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, PharmD, BCOP, Diane Warren, Jorge J. Castillo, MD, Jacob P. Laubach, MD, Claudia E. Paba-Prada, MD, Kenneth C. Anderson, MD, Paul G. Richardson, Edie A. Weller, PhD, Steven P Treon, MD MA, PhD

Blood (2014) 124 (21): 3081.

https://doi.org/10.1182/blood.V124.21.3081.3081

Published: 2014

Journal Articles

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Jacob P. Laubach, MD, Kenneth H. Shain, MD PhD, Rachid Baz, MD, Erica N Boswell, BS, Patrick M Henrick, MPH, Abdel Kareem Azab, Bpharm, PhD, Courtney Hanlon, Stacey Chuma, BSN, Houry Leblebjian, PharmD, BCOP, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Diane Warren, Philippe Armand, MD PhD, Claudia E. Paba-Prada, MD, Nikhil C. Munshi, MD, Robert L Schlossman, MD, Kenneth C. Anderson, MD, Paul G. Richardson

Blood (2014) 124 (21): 5777.

https://doi.org/10.1182/blood.V124.21.5777.5777

Published: 2014

Journal Articles

Administration Of An Oral PDE5 Inhibitor, Tadalafil In Conjunction With a Lenalidomide Containing Regimen In Patients With Multiple Myeloma

Nilanjan Ghosh, MD, PhD, Lakshmi Rudraraju, MS, Xiaobu Ye, MD, MS, Kimberly Noonan, PhD, MPH, Carol Ann Huff, M.D., Ivan M. Borrello, MD

Blood (2013) 122 (21): 1959.

https://doi.org/10.1182/blood.V122.21.1959.1959

Published: 2013

Journal Articles

Dissecting The Potential Role Of Prevnar As An Anti-Myeloma Vaccine

Kimberly Noonan, PhD, MPH, Lakshmi Rudraraju, MS, Anna Ferguson, RN, Amy Sidorski, NP, Andrea Casildo, BS, Ervin Griffin, Susan Lee, BS, Nilanjan Ghosh, MD, PhD, William Matsui, MD, Carol Huff, M.D., Ivan M. Borrello, MD

Blood (2013) 122 (21): 1980.

https://doi.org/10.1182/blood.V122.21.1980.1980

Published: 2013

Journal Articles

Enrichment of Allogeneic Tumor Antigen-Specific T Cells From Bone Marrow (BM) of Patients Treated with High-Dose Post-Transplant Cyclophoshamide (Cy) – A Novel Approach to Adoptive Immunotherapy

Kimberly Noonan, MPH, Leo Luznik, MD, Ivan M. Borrello, MD

Blood (2011) 118 (21): 647.

https://doi.org/10.1182/blood.V118.21.647.647

Published: 2011

Journal Articles

Phase I/II Study of Marrow Infiltrating Lymphocytes (MILs) Generates Measurable Myeloma-Specific Immunity in the Autologous Stem Cell Transplant (SCT) Setting

Kimberly Noonan, MPH, Carol A. Huff, MD, Janice M Davis Sproul, MAS, MT(ASCP), SBB, Mario Victor M Lemas, PhD, Lakshmi Rudraraju, MS, Leo Luznik, Jonathan Powell, MD, PhD, Javier Bolaños-Meade, Jeffrey Bitzan, MT, Susan Fiorino, MT(ASCP), William Matsui, MD, Richard J. Jones, MD, Ivan M. Borrello, MD

Blood (2011) 118 (21): 997.

https://doi.org/10.1182/blood.V118.21.997.997

Published: 2011

NARROW

Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma

Treating MRD Positivity in Multiple Myeloma: An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Long-Term Remissions in Patients with Low Disease Burden

An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Durable Remissions and Sustained Immunological Responses in Multiple Myeloma

Superior Efficacy of CAR-T Cells Using Marrow-Infiltrating Lymphocytes (MILs TM ) As Compared to Peripheral Blood Lymphocytes (PBLs)

Marrow-Infiltrating Lymphocytes (MILs) Provide a Robust Platform for CAR-T Cell Therapy

Progression Risk-Based Classification of Asymptomatic Waldenström Macroglobulinemia

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression

Impact of Bone Marrow Biopsy on Risk Stratification of Low-Risk IgG MGUS Patients

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Allogeneic Myeloma GVAX with Lenalidomide Enhances Progression Free Survival through the Generation of Tumor Specific Immunity in Patients in Near Complete Remission

Impaired Response to Influenza Vaccination in AML Patients Post-Chemotherapy Associated with a Highly Atypical B-Cell Profile

Lenalidomide Immunomodulation with an Allogeneic Myeloma GVAX in a Near Complete Remission Induces Durable Clinical Remissions

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Administration Of An Oral PDE5 Inhibitor, Tadalafil In Conjunction With a Lenalidomide Containing Regimen In Patients With Multiple Myeloma

Dissecting The Potential Role Of Prevnar As An Anti-Myeloma Vaccine

Enrichment of Allogeneic Tumor Antigen-Specific T Cells From Bone Marrow (BM) of Patients Treated with High-Dose Post-Transplant Cyclophoshamide (Cy) – A Novel Approach to Adoptive Immunotherapy

Phase I/II Study of Marrow Infiltrating Lymphocytes (MILs) Generates Measurable Myeloma-Specific Immunity in the Autologous Stem Cell Transplant (SCT) Setting

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only